AlphaFold predicted structure
GSPT2 · Q8IYD1

Mean pLDDT
74.2/ 100
Confident
628 residues
Confidence breakdown
- Very high(≥ 90)48%
- Confident(70–90)21%
- Low(50–70)4%
- Very low(< 50)28%
AlphaFold (Jumper et al., 2021) · CC BY 4.0
G1 to S phase transition 2
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Fetal anomalies
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesDDG2P
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesIntellectual disability
X-LINKED: hemizygous mutation in males, biallelic mutations in femalesautism
Seizure
Delayed speech and language development
cancer
hepatocellular carcinoma
endometrial cancer
spinal muscular atrophy
neoplasm
laryngotracheoesophageal cleft
Atrophy/Degeneration affecting the central nervous system
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Eukaryotic peptide chain release factor GTP-binding subunit ERF3B
GTPase component of the eRF1-eRF3-GTP ternary complex, a ternary complex that mediates translation termination in response to the termination codons UAA, UAG and UGA (PubMed:11524954, PubMed:15987998, PubMed:17562865). GSPT2/ERF3B mediates ETF1/ERF1 delivery to stop codons: The eRF1-eRF3-GTP complex binds to a stop codon in the ribosomal A-site (PubMed:15987998). GTP hydrolysis by GSPT2/ERF3B induces a conformational change that leads to its dissociation, permitting ETF1/ERF1 to accommodate fully in the A-site (PubMed:15987998). Component of the transient SURF complex which recruits UPF1 to stalled ribosomes in the context of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons (PubMed:19417104)
GSPT2 · Q8IYD1

Mean pLDDT
74.2/ 100
Confident
628 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0